Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE

Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE

BackgroundUmbilical cord blood (UCB)-derived CD4+CD25+CD127low regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition...

Full description

Saved in:
Bibliographic Details
Main Authors: Mi-Ae Lyu, Ximing Tang, Maria Gabriela Raso, Meixian Huang, Ke Zeng, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
adoptive cell therapy
regulatory T cells (Tregs)
allogeneic
umbilical cord blood (UCB)
ruxolitinib
JAK/STAT pathway
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1449693/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items